United States-based Johnson & Johnson has started final stage testing of its COVID-19 vaccine candidate, it was reported on Monday.
The company is testing the vaccine with 60,000 volunteers from around the globe including subjects from the US, South Africa, Brazil, Argentina, Columbia, and Chile.
The firm aims to produce a billion doses of the vaccine on a not for profit basis if proven effective. The vaccine requires one dose and also does not need freezing and can remain viable in its liquid form for several months.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine